

Resource Summary Report

Generated by [dkNET](#) on Sep 7, 2026

Anti-Annexin V Monoclonal Antibody, V500 Conjugated

RRID:AB_10694254

Type: Antibody

Proper Citation

BD Biosciences Cat# 561501, RRID:AB_10694254

Antibody Information

URL: http://antibodyregistry.org/AB_10694254

Proper Citation: BD Biosciences Cat# 561501, RRID:AB_10694254

Target Antigen: Annexin V V500

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Anti-Annexin V Monoclonal Antibody, V500 Conjugated

Description: This monoclonal targets Annexin V V500

Target Organism: human

Antibody ID: AB_10694254

Vendor: BD Biosciences

Catalog Number: 561501

Record Creation Time: 20231110T070215+0000

Record Last Update: 20260829T023420+0000

Ratings and Alerts

No rating or validation information has been found for Anti-Annexin V Monoclonal Antibody, V500 Conjugated.

No alerts have been found for Anti-Annexin V Monoclonal Antibody, V500 Conjugated.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Goupille L, et al. (2026) Targeting systemic and tumor metabolic balances with ketogenic diets enhance efficacy of therapy in FLT3-ITD acute myeloid leukemia. Cell reports, 45(4), 117185.

Sabatier M, et al. (2023) C/EBP β Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress-Induced Ferroptosis in FLT3-Mutant Leukemia. Cancer discovery, 13(7), 1720.

Basar R, et al. (2021) Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy. Cell reports, 36(3), 109432.